Skip to content

Evaluation of an Injection Management Protocol for Fulvestrant in Endocrine Therapy: A Preliminary Study

Construction and Preliminary Evaluation of an Injection Management Protocol for Fulvestrant in Endocrine Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120782
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-08-10
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Intervention Group (Nurses):Based on the previously constructed evidence-based intervention protocol for fulvestrant injection management, the following implementation activities will be carried out:
Intervention Group (Patients):For Patients: In addition to the routine verbal education provided to the control group, enhanced intervention measures will be implemented, including: 1) Create and dist

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients: (1)Pathologically diagnosed with breast cancer and having received =18 years; (4)Signed informed consent, voluntarily participating in the intervention trial. 2. Nurses: (1)Engaged in clinical nursing practice; (2)Possess a valid Nurse Practicing Certificate; (3)Voluntarily participate in the study and provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Exclusion Criteria for Patients: (1)In the terminal stage of disease or in critical condition; (2)History of psychiatric disorders, or dysfunction in sensory perception such as pain, temperature, or touch sensation; (3)Injection site already showing signs of adverse reactions such as bruising, ecchymosis, subcutaneous induration, redness, or swelling; (4)Bleeding tendency, with abnormal platelet count or coagulation function. 2. Exclusion Criteria for Nurses: (1)Nurses absent from duty due to sick leave, maternity leave, external training, or other reasons; (2)Non-permanent medical staff such as trainees, interns, or rotating personnel.

Design outcomes

Primary

MeasureTime frame
Injection site pain intensity;Incidence and severity of local induration;Incidence of drug leakage;

Secondary

MeasureTime frame
Adherence to Self-Management;Level of Knowledge on Fulvestrant Injection Management Among Nurses and Patients;Nurses' Adherence to Fulvestrant Injection Administration Protocols;Nurses' and Patients' Experiences of the Intervention;

Countries

China

Contacts

Public ContactZhang Xiaoju

Fudan University Shanghai Cancer Center

shirlyzxj@126.com+86 180 1731 2793

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026